<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684799</url>
  </required_header>
  <id_info>
    <org_study_id>652-123</org_study_id>
    <nct_id>NCT02684799</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination</brief_title>
  <official_title>A Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole (OME) and Famotidine (FAM), on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tobira Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tobira Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess
      the Effect of the Acid Reducing Agents, Omeprazole and Famotidine, on the PK of CVC
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2016</start_date>
  <completion_date type="Actual">April 11, 2016</completion_date>
  <primary_completion_date type="Actual">April 11, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Assessment of CVC, as measured by maximum plasma concentration (Cmax)</measure>
    <time_frame>Days 1, 7, and 13 for Part 1 Group 1. Days 1, 5, 9, and 13 for Part 1 Group 2.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessment of CVC, as measured by minimum plasma concentration (Cmin)</measure>
    <time_frame>Days 1, 7, and 13 for Part 1 Group 1. Days 1, 5, 9, and 13 for Part 1 Group 2.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessment of CVC, as measured by area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Days 1, 7, and 13 for Part 1 Group 1. Days 1, 5, 9, and 13 for Part 1 Group 2.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Adverse Events</measure>
    <time_frame>23 days</time_frame>
    <description>Evaluate adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Clinical Laboratory Tests</measure>
    <time_frame>Baseline and 23 days</time_frame>
    <description>Evaluate changes from baseline in clinical laboratory tests including serum chemistry, hematology and urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in 12-lead ECGs</measure>
    <time_frame>Baseline and 23 days</time_frame>
    <description>Evaluate changes from baseline in 12-lead ECGs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Vital Signs</measure>
    <time_frame>Baseline and 23 days</time_frame>
    <description>Evaluate changes from baseline in vital signs, including blood pressure and pulse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Physical Examinations</measure>
    <time_frame>Baseline and 23 days</time_frame>
    <description>Evaluate changes from baseline in physical examinations</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1 Group 1 (Cenicriviroc)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 Group 1 (12 subjects) will receive CVC 150 mg on Days 1, 7 and 13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Group 1 (Omeprazole)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part 1 Group 1 (12 subjects) will receive Omeprazole 20 mg from Days 2-7, and Omeprazole 40 mg from Days 8-13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Group 2 (Cenicriviroc)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 Group 2 (12 subjects) will receive CVC 150 mg on Days 1, 5, 9 and 13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Group 2 (Famotidine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part 1 Group 2 (12 subjects) will receive Famotidine 40 mg on Days 5, 9 and 13.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Cenicriviroc)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2 (24 subjects) will receive Cenicriviroc from Days 1-10 and Days 11-20.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Omeprazole)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part 2 (24 subjects) will receive Omeprazole from Days 11-20.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cenicriviroc</intervention_name>
    <arm_group_label>Part 1 Group 1 (Cenicriviroc)</arm_group_label>
    <arm_group_label>Part 1 Group 2 (Cenicriviroc)</arm_group_label>
    <arm_group_label>Part 2 (Cenicriviroc)</arm_group_label>
    <other_name>Cenicriviroc 150 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <arm_group_label>Part 1 Group 1 (Omeprazole)</arm_group_label>
    <arm_group_label>Part 2 (Omeprazole)</arm_group_label>
    <other_name>Omeprazole 20 mg</other_name>
    <other_name>Omeprazole 40 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <arm_group_label>Part 1 Group 2 (Famotidine)</arm_group_label>
    <other_name>Famotidine 40 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be informed of the nature of the study and have provided written informed voluntary
             consent.

          -  Have a BMI ≥ 18.0 and ≤ 35.0 kg/m2.

          -  Be in good general health with no clinically relevant abnormalities based on medical
             history, physical examination, clinical laboratory evaluations (clinical chemistry,
             hematology, urinalysis), and 12-lead ECG that, in the opinion of the Investigator,
             would affect subject safety.

          -  Be able to communicate effectively with the Investigator and other study center
             personnel and agree to comply with the study procedures and restrictions.

        Exclusion Criteria:

          -  Any disease or condition that might affect drug absorption, metabolism, or excretion,
             or clinically significant cardiovascular, hematological, renal, hepatic, pulmonary,
             endocrine, gastrointestinal, immunological, dermatological, neurological, or
             psychiatric disease, as determined by the Investigator and, if necessary, the
             Sponsor's Medical Monitor.

          -  History of stomach or intestinal surgery, except for fully healed appendectomy and/or
             cholecystectomy which will be allowed.

          -  Clinically significant illness or clinically significant surgery within 4 weeks before
             the administration of study medication.

          -  History of GERD, heartburn, or nausea more than once a month, or any similar symptoms
             requiring the regular use of antacids, or any use of H2 histamine blockers or
             proton-pump inhibitors over the past 3 months.

          -  History of achlorhydria, pernicious anemia, or peptic ulcers over the past 6 months.

          -  Have a positive Helicobacter pylori urea breath test.

          -  Known or suspected hypersensitivity or allergic reaction to any of the components of
             CVC, OME or FAM tablets.

          -  History of malignancy, with the exception of cured basal cell or squamous cell
             carcinoma of the skin.

          -  If female, is pregnant or breast feeding, or has a positive pregnancy test result
             prior to the first dose of study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Star Seyedkazemi, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Tobira Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SeaView Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2016</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Famotidine</mesh_term>
    <mesh_term>TAK-652</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

